Kris Chavez, Founder & Chief Operating Officer Kris brings extensive leadership experience in all stages of biopharmaceutical development involving antibodies, peptides and small molecules. Prior to founding Innomab, Kris was Vice- President for Project Management at Cambridge Antibody Technology (CAT) Inc. where she was responsible for Program Management. Kris was Project Director at Genencor developing an HBV vaccine and immunotoxins in oncology. At Nektar (Inhale), Kris developed antibody treatments for asthma, chronic obstructive pulmonary disease and multiple sclerosis. She led the Project Management function at Oread, Inc., a contract research organization. Prior to that she had a successful 20+ year career at Syntex/Roche where she held a number of increasingly responsible CMC positions. She earned her B.A. in Biological Sciences from the University of California, Berkeley. Kim Graham, Founder & Chief Executive Officer Kim brings extensive leadership skills. Prior to forming Innomab, Kim was General Manager and Director of Cambridge Antibody Technology, Inc., responsible for the CAT US site and projects. Over his career, Kim has contributed to the development of numerous successfully-marketed pharmaceutical products. Kim's experience includes Vice-President of Drug Development and Vice- President and Director of Drug Evaluation at Roche Bioscience along with numerous development positions of increasing responsibility at Syntex. Over a 19-year period at Syntex, he rose to Vice-President and Director of the multi-country New Molecules Program Management Team. Kim currently sits on AbGenomics International Inc.’s Board of Directors. Kim has a B.A. from Stanford University and an M.A. from the University of Oregon, both in Biology. Chuck Smith, MD, PhD, Founder & Chief Medical Officer Chuck brings extensive clinical development industry experience with emphasis in early stage oncology. Prior to Innomab, Chuck was Vice-President, Clinical Development at Cambridge Antibody Technology. He also led Clinical Development at Genencor. At Novartis' Oncology headquarters, Chuck had a six-year stint where he led the international clinical development of several novel compounds. Chuck trained in Internal Medicine at the Albert Einstein College of Medicine, New York City and was a Clinical Associate at the National Cancer Institute (NCI) in Bethesda, Maryland. Chuck is licensed to practice medicine and has been certified by the American Board of Internal Medicine. Chuck holds M.D. & Ph.D. degrees from the State University of New York, Downstate Medical Center, and a B.S.degree from The Pennsylvania State University. |
Management Team
 |
| |
 |
| |
 |
| |
 |
